934240-30-9
934240-30-9 structure
- Name: CNV1014802
- Chemical Name: (5R)-5-{4-[(2-Fluorobenzyl)oxy]phenyl}-L-prolinamide
- CAS Number: 934240-30-9
- Molecular Formula: C18H19FN2O2
- Molecular Weight: 314.35400
- Catalog: Signaling Pathways Membrane Transporter/Ion Channel Sodium Channel
- Create Date: 2017-06-17 20:52:46
- Modify Date: 2024-01-09 19:27:27
-
CNV1014802(GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.IC50 value: Target: sodium channel blockerLike lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. CNV1014802 received orphan-drug designation from the US Food and Drug Administration in July 2013.
| Name | (5R)-5-{4-[(2-Fluorobenzyl)oxy]phenyl}-L-prolinamide |
|---|---|
| Synonyms | CNV1014802 |
| Description | CNV1014802(GSK-1014802) is a novel small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.IC50 value: Target: sodium channel blockerLike lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. CNV1014802 received orphan-drug designation from the US Food and Drug Administration in July 2013. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C18H19FN2O2 |
|---|---|
| Molecular Weight | 314.35400 |
| Exact Mass | 314.14300 |
| PSA | 65.34000 |
| LogP | 4.16160 |
|
~%
934240-30-9 |
| Literature: GLAXO GROUP LIMITED Patent: WO2007/42239 A1, 2007 ; Location in patent: Page/Page column 43-44 ; WO 2007/042239 A1 |
|
~%
934240-30-9 |
| Literature: CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
|
~%
934240-30-9 |
| Literature: CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
|
~%
934240-30-9 |
| Literature: CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
|
~%
934240-30-9 |
| Literature: CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
|
~%
934240-30-9 |
| Literature: CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
|
~%
934240-30-9 |
| Literature: CONVERGENCE PHARMACEUTICALS LIMITED; ZAJAC, Matthew, Allen Patent: WO2011/29762 A1, 2011 ; WO 2011/029762 A1 |
